<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02371746</url>
  </required_header>
  <id_info>
    <org_study_id>ENV515-01</org_study_id>
    <nct_id>NCT02371746</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma</brief_title>
  <official_title>A Multi-Center, Three-Stage, Open-Label, Prospective, Active-Comparator-Controlled Phase 2a Study of ENV515 (Travoprost) Intracameral Implant in Patients With Bilateral Ocular Hypertension or Early Primary Open-Angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Envisia Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Envisia Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multiple cohort study that will evaluate the safety and efficacy of ENV515
      travoprost XR in patients with open-angle glaucoma or ocular hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 1, 2015</start_date>
  <completion_date type="Anticipated">February 13, 2019</completion_date>
  <primary_completion_date type="Actual">June 29, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Intraocular Pressure (IOP) in the study eye</measure>
    <time_frame>Cohort 1 - Day 25</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in IOP in the study eye</measure>
    <time_frame>Cohorts 2 and 3 - Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in IOP in the study eye</measure>
    <time_frame>Cohorts 2 and 3 - Day 42</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in IOP in the study eye</measure>
    <time_frame>Cohorts 2 and 3 - Day 84</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in time-matched IOP measurements for study eye and non-study eye at all other time points and visits</measure>
    <time_frame>Cohort 2 - Months 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, and 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in time-matched IOP measurements for study eye and non-study eye at all other time points and visits</measure>
    <time_frame>Cohort 3 - Months 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Glaucoma and Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>ENV515 Travoprost XR Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study Eye: Single dose of ENV515 travoprost XR Dose A administered on Day 1. Non-Study Eye: TRAVATAN Z administered once a day from Day 1 to Day 25.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ENV515 Travoprost XR Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study Eye: Single dose of ENV515 travoprost XR Dose B administered on Day 1. Non-Study Eye: TRAVATAN Z administered once a day from Day 1 to Day 25.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ENV515 Travoprost XR Dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study Eye: Single dose of ENV515 travoprost XR Dose C administered on Day 1. Non-Study Eye: TRAVATAN Z administered once a day from Day 1 to Day 25.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ENV515 Travoprost XR Dose D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study Eye: Single dose of ENV515 travoprost XR Dose D administered on Day 1. Non-Study Eye: TRAVATAN Z administered once a day from Day 1 to Day 25.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ENV515 Travoprost XR Dose E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study Eye: Single dose of ENV515 travoprost XR Dose E administered on Day 1. Non-Study Eye: Timolol maleate ophthalmic solution 0.5% administered twice daily from Day 1 to Month 12, Month 18, or up to Month 21.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ENV515 Travoprost XR Dose F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study Eye: Single dose of ENV515 travoprost XR Dose F administered on Day 1. Non-Study Eye: Timolol maleate ophthalmic solution 0.5% administered twice daily from Day 1 to Month 12, Month 18, or up to Month 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ENV515 Travoprost XR Dose G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study Eye: Single dose of ENV515 travoprost XR Dose G administered on Day 1. Non-Study Eye: Timolol maleate ophthalmic solution 0.5% administered twice daily from Day 1 to Month 12, Month 18, or up to Month 24.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ENV515 Travoprost XR</intervention_name>
    <arm_group_label>ENV515 Travoprost XR Dose A</arm_group_label>
    <arm_group_label>ENV515 Travoprost XR Dose B</arm_group_label>
    <arm_group_label>ENV515 Travoprost XR Dose C</arm_group_label>
    <arm_group_label>ENV515 Travoprost XR Dose D</arm_group_label>
    <arm_group_label>ENV515 Travoprost XR Dose E</arm_group_label>
    <arm_group_label>ENV515 Travoprost XR Dose F</arm_group_label>
    <arm_group_label>ENV515 Travoprost XR Dose G</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRAVATAN Z</intervention_name>
    <arm_group_label>ENV515 Travoprost XR Dose A</arm_group_label>
    <arm_group_label>ENV515 Travoprost XR Dose B</arm_group_label>
    <arm_group_label>ENV515 Travoprost XR Dose C</arm_group_label>
    <arm_group_label>ENV515 Travoprost XR Dose D</arm_group_label>
    <other_name>travoprost</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Timolol maleate ophthalmic solution 0.5%</intervention_name>
    <arm_group_label>ENV515 Travoprost XR Dose E</arm_group_label>
    <arm_group_label>ENV515 Travoprost XR Dose F</arm_group_label>
    <arm_group_label>ENV515 Travoprost XR Dose G</arm_group_label>
    <other_name>timolol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of either ocular hypertension or open angle glaucoma in both eyes.

          -  Are currently treated with topical PGA for ocular hypertension in both eyes.

          -  Patients who in the opinion of the Investigator: have an IOP in both eyes that is
             considered to be adequately controlled, can be safely withdrawn from IOP medications
             in both eyes during the washout period, and who are not considered to be at
             significant risk for disease progression throughout the trial.

        Exclusion Criteria:

          -  Eye surgery (including cataract surgery) within the past 3 months.

          -  History of glaucoma related surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92843</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Inglewood</city>
        <state>California</state>
        <zip>90301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Redding</city>
        <state>California</state>
        <zip>96002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morrow</city>
        <state>Georgia</state>
        <zip>30260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2015</study_first_submitted>
  <study_first_submitted_qc>February 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2015</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Travoprost</mesh_term>
    <mesh_term>Maleic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

